ST3GAL1 and breast cancer: Lin and colleagues showed that ST3GAL1-mediated sialylation of CD55 renders better inhibition of the complement system at C3 level and that ST3GAL1 silencing results in increased C3 deposition and increased CDC-mediated killing of breast cancer cells (63).